; or (7) for having violated section 301(jjj) if such person acted in good faith and had a reasonable basis for not notifying as required under section 506C ; and (B) by adding at the end the following: (h) Notwithstanding subsection (a), any manufacturer who violates section 301(jjj) shall be subject to a civil penalty in an amount not to exceed $50,000 per violation. . 4. Supporting continuous manufacturing to prevent shortages for susceptible drugs (a) In general Subtitle B of title III of the 21st Century Cures Act is amended by inserting after section 3016 ( 21 U.S.C. 399h ) the following: 3017. Grants for continuous manufacturing to prevent drug shortages (a) In general The Secretary of Health and Human Services shall solicit and, beginning not later than one year after the date of enactment of the Drug Shortages Prevention and Quality Improvement Act , receive, requests for grants from institutions of higher education or nonprofit entities engaged in the manufacture of sterile injectable drugs for the purpose of upgrading drug establishment to continuous manufacturing or other advanced manufacturing capabilities. (b) Grant criteria An institution of higher education or a nonprofit entity shall be eligible for a grant under this section if such institution or entity manufactures a drug that— (1) is categorized as an essential medicine under Executive Order 13944; (2) is a sterile injectable drug